Might 4 (Reuters) – Regeneron Prescribed drugs Inc's (REGN.O) first-quarter gross sales of blockbuster eye drug Eylea got here in beneath Wall Avenue targets on Thursday as competitors heated up, dragging the corporate's shares greater than 5% decrease in early commerce.
Eylea, collectively developed with Bayer AG (BAYGn.DE), has been a key progress driver for Regeneron for years, however its gross sales have fallen over the previous few quarters, partly attributable to rising competitors from Roche's (ROG.S) Vabysmo for the reason that rival secured U.S. approval final 12 months.
“I say there's just a little little bit of a new-kid-in-town form of impact,” mentioned EF Hutton & Co analyst Michael King, as medical doctors could also be keen to offer Vabysmo a strive as a result of it's the latest drug available in the market.
Regeneron is pinning its hopes on approval for a high-dose model of Eylea that would permit longer intervals between injections for sufferers – a function that analysts count on will provide the corporate a greater protection towards Vabysmo.
The quarterly outcomes from Regeneron “place much more emphasis on the necessity for near-flawless execution with the upcoming approval and sure launch” of high-dose Eylea, BMO Capital Markets analyst Evan Seigerman mentioned in a be aware.
Quarterly Eylea gross sales of $2.28 billion missed analysts' expectations of $2.43 billion, in accordance Refinitiv knowledge.
Low-dose Eylea is predicted to develop into a smaller share of the corporate's income if the higher-dose model positive factors approval, Regeneron CEO Leonard Schleifer mentioned.
The U.S. well being regulator's determination on the brand new model is predicted by June 27.
The corporate has additionally been leaning on its anti-inflammatory drug Dupixent – a remedy at present permitted for 5 indications together with bronchial asthma and atopic dermatitis, or eczema.
Quarterly gross sales of Dupixent, recorded by associate Sanofi (SASY.PA), rose about 37% to $2.49 billion, serving to Regeneron beat quarterly revenue estimates.
Analysts mentioned the beat was additionally pushed by better-than-expected collaboration revenues.
Reporting by Sriparna Roy and Raghav Mahobe in Bengaluru; Modifying by Devika Syamnath
: .
